Recently, Blue Sail Medical (002382.SZ) announced that its cardiovascular and cerebrovascular business unit, Blue Sail Biosensors, has raised a total of RMB 1 billion in funding. The Series A2 round introduced an additional RMB 100 million, following a RMB 900 million Series A1 round in January 2024. This round of funding, which includes contributions from the Beijing New Aerotropolis, marks a further acceleration of Blue Sail Medical's strategic layout in the cardiovascular and cerebrovascular field.

CEC Capital continues to serve as the exclusive financial advisor to Blue Sail Biosensors in this transaction. The cumulative amount of this round of funding reaches RMB 1 billion, setting a new record for the largest single round of private equity financing in China's medical device sector over the past two years.

This Series A2 funding not only provides further financial support for Blue Sail Biosensors but also assists the company in gradually building a northern headquarters for high-end medical devices in southern Beijing, near the airport. By leveraging Beijing's medical resources and the policy advantages of the airport area, Blue Sail Medical aims to build an integrated service platform. This initiative aligns with the national Beijing-Tianjin-Hebei coordinated development strategy and is expected to significantly contribute to the advancement of the life and health industry.